Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis.
D000293:Adolescent; D001168:Arthritis / Q000150:complications; D001219:Aspartate Aminotransferases / Q000097:blood; D001706:Biopsy; D003404:Creatinine / Q000097:blood; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005334:Fever; D005634:Fructose-Bisphosphate Aldolase / Q000032:analysis; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000201:enzymology; D009220:Myositis / Q000188:drug therapy* / Q000201:enzymology; D010053:Ovary / Q000473:pathology; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011507:Proteinuria; D012867:Skin / Q000473:pathology; D014556:Urine / Q000032:analysis
D003520:Cyclophosphamide; D003404:Creatinine; D001219:Aspartate Aminotransferases; D005634:Fructose-Bisphosphate Aldolase; D011241:Prednisone